Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(9 sites)
China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang The First People's Hospital of Changzhou, Changzhou, Jiangsu Jiangsu People's Hospital, Nanjing, Jiangsu Northern Jiangsu People's Hospital, Yangzhou, Jiangsu Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality Sanjun Cai, Shanghai, Shanghai Municipality Renji Hospital，Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality Zhejiang Cancer Hospita, Hangzhou, Zhejiang Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang